Antiviral Drugs Market Insights, Size & Growth Forecast To 2032

According to a new report published by K D Market Insights, titled, “Antiviral Drugs Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global antiviral drugs market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032. The increasing prevalence of viral infections, growing awareness about available vaccines, and the introduction of generic versions of antiviral medicines. Which are the major factors augmenting the growth of the global antiviral drugs market.

The increasing prevalence of viral infections, such as HIV, herpes, influenza, and hepatitis, growing awareness about the availability of vaccines for viral infections are further expected to create ample growth opportunities for the global antiviral drugs market during the forecast period i.e., 2023-2032. Moreover, pharmaceutical companies are investing in research and development to develop more effective treatments for viral infections, is increasing has propelled market expansion collaborations among key players in the market for the development and manufacturing of antiviral drugs, is expected to contribute towards the market growth during the period.

The North America region accounted for the largest share in the global antiviral drugs market in 2022. The region is further projected to continue dominating in the market and also register the highest CAGR in the market during the forecast period. This can be attributed to the high treatment rate of viral infections, government initiatives to combat viral infections, and ongoing research and development activities.

According to type, the branded segment accounted for the largest market share in the antiviral drugs market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.

The global antiviral drugs market is segmented into drug class, type, application, distribution channel and region. Based on drug class, the market is bifurcated into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, others. Based on type, it is classified into branded, generics. Based on application, it is classified into HIV, hepatitis, herpes, influenza. Based on distribution channel, it is classified into hospital pharmacies, retail pharmacies, online pharmacies

The global antiviral drugs market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).

Key Insights of Antiviral Drugs Market

On the basis of type, the branded segment accounted for the largest market share in the antiviral drugs market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
On the basis of region, North America accounted for the largest share in the global antiviral drugs market in 2022. The region is further projected to continue dominating in the market during the forecast period.
On the basis of region, Asia-Pacific is estimated to account for the second largest share in the market during the forecast period.

Some of the major antiviral drugs companies profiled in the report include Merck & Co., Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, AbbVie Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Cipla Inc., AstraZeneca, and Pfizer Inc.